Fruquintinib hydrochloride bulk supplier for pharma manufacturers

Fruquintinib Hydrochloride 1 mg, 5 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 1 mg, 5 mg

Reference Brands: Fruzaqla (USA/EU), Elunate (USA/EU)

Fruquintinib is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor used for the treatment of metastatic colorectal cancer. It works by selectively blocking VEGFR-1, VEGFR-2, and VEGFR-3, thereby inhibiting tumor angiogenesis and slowing cancer growth.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Fruquintinib Hydrochloride? List it or send an offer →

Product Description:

Fruquintinib blocks all three vascular endothelial growth factor receptors with high selectivity, and the selectivity is the point. Earlier antiangiogenic kinase inhibitors hit many off-target kinases, which produced toxicity that forced dose reduction below the level needed to suppress angiogenesis properly. A cleaner profile allows sustained target coverage, which is what matters when the objective is to starve a tumour rather than to poison it.

It is used for metastatic colorectal cancer in patients who have already received fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, an anti-VEGF agent, and where appropriate an anti-EGFR antibody — that is, in the late-line setting where options are nearly exhausted. It is taken once daily for three weeks of each four-week cycle. Hypertension is the most frequent adverse effect and requires monitoring and treatment. Hand-foot skin reaction, proteinuria, dysphonia, bleeding, and impaired wound healing occur.

Sourcing notes. Originator product, on patent, marketed under different brand names in different regions by different partners — the US and European product and the Chinese product are the same molecule under separate registrations. Two capsule strengths support dose reduction. No companion test required. Oral solid, room temperature.

How Fruquintinib Hydrochloride is supplied today, and licensing ahead of patent expiry

Fruquintinib Hydrochloride is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Fruquintinib Hydrochloride, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Fruquintinib Hydrochloride supply →

Back to Listing

Frequently Asked Questions

Fruquintinib hydrochloride is used to treat adults with metastatic colorectal cancer who have been previously treated with chemotherapy and other targeted therapies.

Fruquintinib hydrochloride is made from the active ingredient Fruquintinib, a selective VEGFR inhibitor, combined with hydrochloride to form a stable salt for oral use.

The trade name of Fruquintinib hydrochloride is Fruzaqla and Elunate.

Fruquintinib hydrochloride is developed and manufactured by Hutchmed and licensed to Takeda Pharmaceuticals for global distribution.

The generic name is Fruquintinib hydrochloride.

Brand names include Fruzaqla and Elunate.

Fruquintinib hydrochloride is manufactured in China, Japan, and the United States by Hutchmed and Takeda Pharmaceuticals for international oncology markets.

Fruquintinib is sold as Fruzaqla and Elunate. It is developed and sold by HUTCHMED, and by Takeda outside China. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.